换一批Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
第一作者：
Jan,Braess
第一单位：
Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Klinikum Grosshadern der LMU, München, Germany. jan.braess@med.uni-muenchen.de
作者：
医学主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);阿糖胞苷(Cytarabine);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);非格司亭(Filgrastim);粒细胞集落刺激因子(Granulocyte Colony-Stimulating Factor);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);中年人(Middle Aged);米托蒽醌(Mitoxantrone);中性粒细胞减少(Neutropenia);试点项目(Pilot Projects);聚乙烯二醇类(Polyethylene Glycols);重组蛋白质类(Recombinant Proteins);学会, 医学(Societies, Medical);存活率(Survival Rate);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1182/blood-2008-07-162842
PMID
19131552
发布时间
2021-02-06
- 浏览8
Blood
3903-10页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
